{"entity":{"id":"lajos-pusztai","kind":"person","name":"Lajos Pusztai","aka":[],"tldr":"Translational breast oncologist who co-leads the I-SPY2 platform trial and helped show immunotherapy works in early TNBC.","summary":"Lajos Pusztai (Yale Cancer Center) co-leads the I-SPY2 adaptive neoadjuvant platform, whose durvalumab and pembrolizumab arms provided the first randomised evidence that checkpoint inhibitors raise pathological complete response in triple-negative breast cancer, before KEYNOTE-522 confirmed it. He led the SWOG S1418 adjuvant pembrolizumab trial and has published widely on immune gene signatures. His current focus is response-adapted de-escalation.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pusztai%20L%5BAuthor%5D%20triple-negative%20I-SPY"}],"tags":["tnbc","platform-trial","biomarkers"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab","durvalumab"],"companies":[],"institutions":["yale-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-cell"],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Co-Leader, Genetics, Genomics and Epigenetics Program, Yale Cancer Center","institutionId":"yale-cancer-center","specialisms":["Triple-negative breast cancer","Adaptive platform trials","Immune biomarkers","Neoadjuvant therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pusztai%20L%5BAuthor%5D%20triple-negative%20I-SPY"}],"papers":[{"title":"Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: results from the adaptively randomized I-SPY2 trial","journal":"Cancer Cell","year":2021,"doi":"10.1016/j.ccell.2021.05.009"},{"title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial","journal":"JAMA Oncology","year":2020,"doi":"10.1001/jamaoncol.2019.6650"}],"orcid":"0000-0001-9632-6686"},"route":"/people/lajos-pusztai/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"yale-cancer-center","kind":"institution","name":"Yale Cancer Center / Smilow Cancer Hospital","route":"/institutions/yale-cancer-center/"}],"journal":[{"id":"cancer-cell","kind":"journal","name":"Cancer Cell","route":"/journals/cancer-cell/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}]}}